Mild cognitive impairment and anti-Alzheimer disease medications: A cross sectional study of the French National Alzheimer Databank (BNA)

Journal of Alzheimer's Disease

Volumn 38, Issue 3, 2014, Pages 541-549

  Tifratene, Karim ^a,b   Sakarovitch, Charlotte ^a   Rouis, Amel ^a   Pradier, Christian ^a   Robert, Philippe ^b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b University of Côte d Azur   (France)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; medications; memantine; mild cognitive impairment

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; FRANCE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; UNIVARIATE ANALYSIS;

ALZHEIMER'S DISEASE; CHOLINESTERASE INHIBITORS; MEDICATIONS; MEMANTINE; MILD COGNITIVE IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; MALE; MEMANTINE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84889640784     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131103     Document Type: Article

References (50)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
2. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P,Winblad B (2006) International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 367, 1262-1270.
3. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr. (2009) Mild cognitive impairment: Ten years later. Arch Neurol 66, 1447-1455.
4. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
5. Busse A, Hensel A,Gühne U, Angermeyer MC, Riedel-Heller SG (2006) Mild cognitive impairment: Long-Term course of four clinical subtypes. Neurology 67, 2176-2185.
6. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ,Willis RJ,Wallace RB (2008) Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 148, 427-434.
7. Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R (2008) Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 63, 494-506.
8. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH (2003) Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 60, 1385-1389.
9. Ritchie K (2004) Mild cognitive impairment: An epidemiological perspective. Dialogues Clin Neurosci 6, 401-408.
10. Petersen RC (2011) Clinical practice. Mild cognitive impairment. N Engl J Med 364, 2227-2234.
11. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B (1999) Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 12, 168-179.
12. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C (2009) Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 66, 1151-1157.
13. Ganguli M, Chang CC, Snitz BE, Saxton JA,Vanderbilt J, Lee CW(2010) Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry 18, 674-683.
14. Feldman HH, Jacova C (2005) Mild cognitive impairment. Am J Geriatr Psychiatry 13, 645-655.
15. Ganguli M, Dodge HH, Shen C, DeKosky ST (2004) Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology 63, 115-121.
16. Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62, 1160-1163.
17. Gauthier S, Touchon J (2005) Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol 62, 1164-1166.
18. Rockwood K, Chertkow H, Feldman HH (2007) Is mild cognitive impairment a valid target of therapy. Can J Neurol Sci 34(Suppl 1), S90-S96.
19. Jean L, Bergeron ME, Thivierge S, Simard M (2010) Cognitive intervention programs for individuals with mild cognitive impairment: Systematic review of the literature. Am J Geriatr Psychiatry 18, 281-296.
20. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388.
21. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK (2009) Donepezil treatment of patients with MCI: A 48-week randomized, placebocontrolled trial. Neurology 72, 1555-1561.
22. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group (2004) Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology 63, 651-657.
23. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study. Lancet Neurol 6, 501-512.
24. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ,Wang D, Brashear HR, Nye JS, (2008) GAL-INT-11/18 Study, Group Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70, 2024-2035.
25. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC (2005) Reines SA; Rofecoxib Protocol 078 study group, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30, 1204-1215.
26. Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad B (2002) Clinical efficacy of piracetam in cognitive impairment: A meta-Analysis. Dement Geriatr Cogn Disord 13, 217-224.
27. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K (2009) Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. J Am Geriatr Soc 57, 686-690.
28. Weston AL,Weinstein AM, Barton C, Yaffe K (2010) Potentially inappropriate medication use in older adults with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 65, 318-321.
29. McClendon MJ, Hernandez S, Smyth KA, Lerner AJ (2009) Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J Alzheimers Dis 16, 577-583.
30. Tifratene K, Duff FL, Pradier C, Quetel, J, Lafay P, Schück S, Benzenine E, Quantin C, Robert P (2012) Use of drug treatments for Alzheimer's disease in France: A study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf 21, 1005-1012.
31. Le Duff F, Develay AE, Quetel, J, Lafay P, Schück S, Pradier C, Robert P (2012) The 2008-2012 French Alzheimer plan: Description of the national Alzheimer information system.J Alzheimers Dis 29, 891-902.
32. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
33. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
34. Crum RM, Anthony JC, Bassett SS, Folstein MF (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 2386-2391.
35. Paradise M, Cooper C, Livingston G (2009) Systematic review of the effect of education on survival in Alzheimer's disease. Int Psychogeriatr 21, 25-32.
36. Cullen B, Fahy S, Cunningham CJ, Coen RF, Bruce I, Greene E, Coakley D, Walsh JB, Lawlor BA (2005) Screening for dementia in an Irish community sample usingMMSE:Acomparison of norm-Adjusted versus fixed cut-points. Int J Geriatr Psychiatry 20, 371-376.
37. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC (2010) Mild cognitive impairment in clinical care: A survey of American Academy of Neurology members. Neurology 75, 425-431.
38. Frisoni GB, Canu E, Geroldi C, Zanetti O, Zacchi V (2006) Drug prescription in mild cognitive impairment: The physicians' perspective in Italy. Int J Geriatr Psychiatry 21, 1071-1077.
39. Mitchell T, Woodward M, Hirose Y (2008) A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. Int Psychogeriatr 20, 77-85.
40. Okonkwo OC, Griffith HR, Copeland JN, Belue K, Lanza S, Zamrini EY, Harrell LE, Brockington JC, Clark D, Raman R, Marson DC (2008) Medical decision-making capacity in mild cognitive impairment:A3-year longitudinal study. Neurology 71, 1474-1480.
41. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
42. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D (2007) Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 64, 1443-1450.
43. Teng E, Lu PH, Cummings JL (2007) Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 24, 253-259.
44. Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, Albert M (2003) Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord 17, 1-8.
45. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: Systematic review, meta-Analysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-538.
46. Robert PH, Berr C, Volteau M, Bertogliati-Fileau C, Benoit M, Guerin O, Sarazin M, Legrain S, Dubois B, Study PŕeAL, Group (2008) Importance of lack of interest in patients with mild cognitive impairment. Am J Geriatr Psychiatry 16, 770-776.
47. Morris JC (2012) Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 69, 700-708.
48. International Classification of Diseases 10 (ICD-10). World Health Organization. http://www.who.int/classifications/icd /en/.
49. Petersen RC (2003) Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2, 646-653.
50. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.